ABC294640 Sphingosine Kinase-2 Inhibitor for COVID-19
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for COVID-19 caused by SARS-CoV-2 lack effective options that target the underlying viral replication and inflammatory responses, leading to severe respiratory issues and potential resistance concerns.
Innovation Solution
The use of ABC294640, a sphingosine kinase-2 inhibitor, administered as a free base or salt, in combination with a pharmaceutically acceptable carrier material, specifically targeting host cell factors to modulate viral replication and inflammatory responses, is proposed for treating COVID-19, particularly in patients requiring supplemental oxygen.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for COVID-19 are used, then viral replication and inflammatory responses are not effectively targeted, but treatment efficacy is limited and resistance concerns arise
Solution Approach 1:
The patent employs ABC294640 as an intermediary substance that targets host cell factors (sphingosine kinase-2) rather than the virus directly. This mediator approach allows modulation of viral replication and inflammatory responses through host cell mechanisms, thereby improving treatment efficacy while minimizing resistance risks since the target is the host cell rather than the evolving viral genome
Solution Approach 2:
The patent changes the therapeutic parameter from direct viral targeting to host cell factor modulation. By shifting the target from viral proteins to host cell sphingosine kinase-2, the treatment approach fundamentally alters the mechanism of action, enabling effective antiviral and anti-inflammatory effects without the resistance issues associated with direct antiviral agents
2Reliability
If ABC294640 is administered to patients requiring supplemental oxygen, then antiviral and anti-inflammatory effects are achieved, but the complexity of treatment protocol increases
Solution Approach 1:
ABC294640 exhibits multi-functionality by simultaneously providing antiviral effects through inhibition of viral replication and anti-inflammatory effects through modulation of host cell responses. This single agent addresses multiple pathological aspects of COVID-19, simplifying the overall treatment approach despite the specificity of the patient selection criteria
Data Source
AI summary
The disclosure is directed to ABC294640, as free base or as salts thereof, in preparing medicines for treating coronavirus infection or preventing diseases caused by coronavirus infection, and a medicine for preventing coronavirus infection or preventing diseases caused by coronavirus infection.